Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice

Endocrine

Volumn 49, Issue 3, 2015, Pages 683-692

  Ye, Xianlong ^a   Qi, Jianying ^a   Ren, Guiping ^a   Xu, Pengfei ^a   Wu, Yunzhou ^a   Zhu, Shenglong ^b   Yu, Dan ^a   Li, Shujie ^a   Wu, Qiang ^a   Muhi, Rasool Lubna ^a,c   Li, Deshan ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^b JIANGNAN UNIVERSITY   (China)

^c UNIVERSITY OF BAGHDAD   (Iraq)

Author keywords

Diabetes; FGF 21; Hypoglycemic effect; Liraglutide; PEGylation

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIPID; LIRAGLUTIDE; PEGYLATED FIBROBLAST GROWTH FACTOR 21; RECOMBINANT GROWTH FACTOR; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21; GLUCOSE BLOOD LEVEL; MACROGOL DERIVATIVE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE TOLERANCE TEST;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FIBROBLAST GROWTH FACTORS; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; LIPIDS; LIRAGLUTIDE; LIVER FUNCTION TESTS; MALE; MICE; MICE, INBRED C57BL; POLYETHYLENE GLYCOLS;

EID: 84937971503     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0503-8     Document Type: Article

References (48)

1. W. Chen, R.L. Hoo, M. Konishi, N. Itoh, P.C. Lee, H.Y. Ye et al., Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J. Biol. Chem. 286, 34559–34566 (2011)
2. A. Kharitonenkov, T.L. Shiyanova, A. Koester, A.M. Ford, R. Micanovic, E.J. Galbreath et al., FGF-21 as a novel metabolic regulator. J. Clin. Inves. 115, 1627–1635 (2005)
3. W. Wente, A.M. Efanov, M. Brenner, A. Kharitonenkov, A. Köster, G.E. Sandusky et al., Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55, 2470–2478 (2006)
4. X. Huang, C. Yu, C. Jin, C. Yang, R. Xie, D. Cao et al., Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol. Carcinog. 45, 934–942 (2006)
5. T. Coskun, H.A. Bina, M.A. Schneider, J.D. Dunbar, C.C. Hu, Y. Chen et al., FGF21 corrects obesity in mice. Endocrinology 149, 6018–6127 (2008)
6. J. Xu, D.J. Lloyd, C. Hale, S. Stanislaus, M. Chen, G. Sivits et al., FGF21 reverses hepatic steatosis, increases energy expenditure and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250–259 (2009)
7. A. Kharitonenkov, V.J. Wroblewski, A. Koester, Y.F. Chen, C.K. Clutinger, X.T. Tigno et al., The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148, 774–781 (2007)
8. R. Hecht, Y.S. Li, J. Sun, E. Belouski, M. Hall, T. Hager et al., Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS ONE 7, e49345 (2012)
9. B.K. Lee, J.S. Kwon, H.J. Kim, S. Yamamoto, E.K. Lee, Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity. Bioconjug. Chem. 18, 1728–1734 (2007)
10. Y. Mukai, Y. Yoshioka, Y. Tsutsumi, Phage display and PEGylation of therapeutic proteins. Comb. Chem. High Throughput Screen 8, 145–152 (2005)
11. F.M. Veronese, G. Pasut, PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451–1458 (2005)
12. A. Abuchowski, J.R. McCoy, N.C. Palczuk, T. van Es, F.F. Davis, Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252, 3582–3586 (1977)
13. Q. An, Y. Lei, N. Jia, X. Zhang, Y. Bai, J. Yi et al., Effect of site-directed PEGylation of trichosanthin on its biological activity, immunogenicity, and pharmacokinetics. Biomol. Eng. 24, 643–649 (2007)
14. X. Ye, J. Qi, G. Sun, G. Ren, S. Zhu, Y. Wu et al., Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation. Curr. Pharm. Biotechnol. 14, 1287–1298 (2013)
15. Z. Huang, H. Wang, M. Lu, C. Sun, X. Wu, Y. Tan et al., A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS ONE 6, e20669 (2011)
16. B. Zinman, J. Gerich, J.B. Buse, A. Lewin, S. Schwartz, P. Raskin et al., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabet. Care 32, 1224–1230 (2009)
17. D. Russell-Jones, A. Vaag, O. Schmitz, B.K. Sethi, N. Lalic, S. Antic et al., Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 52, 2046–2055 (2009)
18. M. Marre, J. Shaw, M. Brändle, W.M. Bebakar, N.A. Kamaruddin, J. Strand et al., Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med. 26, 268–278 (2009)
19. M. Nauck, A. Frid, K. Hermansen, N.S. Shah, T. Tankova, I.H. Mitha et al., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabet. Care 32, 84–90 (2009)
20. J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, J.H. Brett et al., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39–47 (2009)
21. A. Garber, R. Henry, R. Ratner, P.A. Garcia-Hernandez, H. Rodriguez-Pattzi, I. Olvera-Alvarez et al., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373, 473–481 (2009)
22. J.B. Buse, M. Nauck, T. Forst, W.H. Sheu, S.K. Shenouda, C.R. Heilmann et al., Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381, 117–124 (2013)
23. H. Agersø, L.B. Jensen, B. Elbrønd, P. Rolan, M. Zdravkovic, The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45, 195–202 (2002)
24. M.Y. Liu, W.F. Wang, Y.X. Yu, Y.T. Hou, G.P. Ren, D.S. Li, FGF21 improves glucose uptake and glycogen synthesis of insulin-resistant liver cells. Prog. Biochem. Biophys. 36, 1327–1333 (2009)
25. M.M. Véniant, C. Hale, J. Helmering, M.M. Chen, S. Stanislaus, J. Busby et al., FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS ONE 7, e40164 (2012)
26. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabet. Care 32, S62–S67 (2009)
27. A. Barnett, Dosing of insulin glargine in the treatment of type 2 diabetes. Clin. Ther. 29, 987–999 (2007)
28. J.E. Gerich, Physiology of glucose homeostasis. Diabet. Obes. Metab. 2, 345–350 (2000)
29. D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Holman, R. Sherwin et al., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabet. Care 32, 193–203 (2009)
30. E. Montanya, G. Sesti, A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin. Ther. 31, 2472–2488 (2009)
31. M. Malmenäs, J.R. Bouchard, J. Langer, Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg. Clin. Ther. 35, 795–807 (2013)
32. A. Garber, R.R. Henry, R. Ratner, P. Hale, C.T. Chang, B. Bode et al., Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabet. Obes. Metab. 13, 348–356 (2011)
33. M. Shimoda, Y. Kanda, S. Hamamoto, K. Tawaramoto, M. Hashiramoto, M. Matsuki et al., The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 54, 1098–1108 (2011)
34. L.N. Chen, J. Lyu, X.F. Yang, W.J. Ji, B.X. Yuan, M.X. Chen et al., Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice. Int. J. Mol. Med. 32, 892–900 (2013)
35. M.A. Nauck, M. Hompesch, R. Filipczak, T.D. Le, M. Zdravkovic, J. Gumprecht et al., Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 114, 417–423 (2006)
36. E.D. Berglund, C.Y. Li, H.A. Bina, S.E. Lynes, M.D. Michael, A.B. Shanafelt et al., Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150, 4084–4093 (2009)
37. W. Wei, P.A. Dutchak, X. Wang, X. Ding, X. Wang, A.L. Bookout et al., Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc. Natl. Acad. Sci. USA 109, 3143–3148 (2012)
38. Y. Shao, G. Yuan, Y. Feng, J. Zhang, X. Guo, Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice. Peptides 52, 134–142 (2014)
39. R.C. Moffett, S. Patterson, P.R. Flatt, Effects of Liraglutide on glycaemic control and pancreatic islet morphology in C57BL/KsJ db/db mice with degenerative diabetes. Regul. Pept. 164, 43 (2010)
40. F. Stickel, C. Hellerbrand, Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 59, 1303–1307 (2010)
41. F. Angelico, M. Del Ben, R. Conti, S. Francioso, K. Feole, S. Fiorello et al., Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 90, 1578–1582 (2005)
42. European Diabetes Policy Group, A desktop guide to Type 2 diabetes mellitus. Diabet. Med. 16, 716–730 (1999)
43. American Diabetes Association, Standards of medical care in diabetes—2007. Diabet. Care 30, S4–S41 (2007)
44. C. Postic, R. Dentin, J. Girard, Role of the liver in the control of carbohydrate and lipid homeostasis. Diabet. Metab. 30, 398–408 (2004)
45. L. Agius, Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks. Diabetes 58, 18–20 (2009)
46. L. Lu, C.P. Seidel, T. Iwase, R.K. Stevens, Y.Y. Gong, X. Wang et al., Suppression of GLUT1; a new strategy to prevent diabetic complications. J. Cell. Physiol. 228, 251–257 (2013)
47. B.A. Haber, S. Chin, E. Chuang, W. Buikhuisen, A. Naji, R. Taub, High levels of glucose-6-phosphatase gene and protein expression reflect an adaptive response in proliferating liver and diabetes. J. Clin. Invest 95, 832–841 (1995)
48. K. Prasad, Suppression of phosphoenolpyruvate carboxykinase gene expression by secoisolariciresinol diglucoside (SDG), a new antidiabetic agent. Int. J. Angiol. 11, 107–109 (2007)